BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN EUROPE

被引：0

作者：

Ruff, L. ^{[1
]}

Rezk, M. F. ^{[2
]}

Uhlig, T. ^{[3
]}

Gommers, J. W. ^{[2
]}

机构：

[1] Covance Inc, London, England

[2] Biogen Int GmbH, Zug, Switzerland

[3] Diakonhjemmet Hosp, Oslo, Norway

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS33

引用

页码：A639 / A639

页数：1

共 50 条

[1] ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN SPAIN
Psachoulia, E.
Casahorran, V
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A534
[2] BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN EUROPE
Ruff, L.
Rezk, M. F.
Uhlig, T.
Gommers, J. W.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A639 - A639
[3] ASSESSING THE POTENTIAL COST SAVING POTENTIAL OF IMPLEMENTING BENEPALI®, AN ETANERCEPT BIOSIMILAR, USING DISCOUNT AGREEMENTS FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN SWEDEN
Psachoulia, E.
Holmqvist, K.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A533
[4] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN THREE REGIONS IN ITALY
Psachoulia, E.
Negrini, C.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A534 - A534
[5] ASSESSING THE COST SAVING POTENTIAL OF INTRODUCING BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN FRANCE, ITALY AND SWEDEN
Psachoulia, E.
Bresson, A.
Holmqvist, K.
Negrini, C.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A533
[6] Budget impact analysis of the etanercept biosimilar: the Italian scenario
Ravasio, Roberto
Girolomoni, Giampiero
Gorla, Roberto
[J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2018,
[7] ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF AN ETANERCEPT BIOSIMILAR (SB4) FOR THE TREATMENT OF APPROVED ADULT ETANERCEPT INDICATIONS IN BELGIUM
Psachoulia, E.
Bresson, A.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A529 - A529
[8] ESTIMATION OF THE ADDITIONAL BUDGET SAVING POTENTIAL DUE TO THE RAPID ADOPTION OF AN ETANERCEPT BIOSIMILAR (SB4) FOR THE TREATMENT OF APPROVED ADULT ETANERCEPT INDICATIONS IN SPAIN
Psachoulia, E.
Chouman, S.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A529 - A530
[9] Economic impact of biosimilar etanercept use
Moron, R.
Nieto Gomez, P.
Garcia Fernandez, C.
Alvarez Sanchez, R.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 317 - 317
[10] Analysis of first prescriptions of biosimilar etanercept
Moron, R.
Nieto Gomez, P.
Garcia Fernandez, C.
Alvarez Sanchez, R.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 349 - 349

← 1 2 3 4 5 →